CervoMed (CRVO) officer buys 10,000 shares at $7.57 avg

CervoMed Inc. (CRVO) reported an insider transaction in which its Chief Commercial and Business officer purchased 10,000 shares of common stock in open-market transactions on 11/14/2025 at a weighted average price of $7.57 per share.

Rhea-AI Filing Summary

CervoMed Inc. (CRVO) reported an insider transaction in which its Chief Commercial and Business officer purchased 10,000 shares of common stock in open-market transactions on 11/14/2025 at a weighted average price of $7.57 per share. Following this transaction, the reporting person beneficially owns 10,000 shares, held directly.

According to the filing, the shares were bought in multiple open-market trades at prices ranging from $7.53 to $7.60 per share. The reporting person has undertaken to provide full details of the number of shares purchased at each separate price within this range upon request.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Winton Matthew

Role Chief Commercial and Business

Bought 10,000 shs ($76K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$7.57	$76K

Holdings After Transaction: Common Stock — 10,000 shares (Direct)

Footnotes (2)

1. F1. Shares purchased in open-market transactions.
2. F2. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.53 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CervoMed Inc. (CRVO) report in this Form 4?

The filing reports that the Chief Commercial and Business officer of CervoMed Inc. (CRVO) purchased 10,000 shares of the company’s common stock in open-market transactions.

On what date did the CervoMed (CRVO) insider share purchase occur?

The insider share purchase took place on 11/14/2025, as reported in the Form 4.

What was the purchase price for the 10,000 CervoMed (CRVO) shares?

The 10,000 shares were bought at a weighted average price of $7.57 per share, with individual trades executed between $7.53 and $7.60.

How many CervoMed (CRVO) shares does the reporting person own after this transaction?

After the reported transaction, the insider beneficially owns 10,000 shares of CervoMed common stock, held directly.

What is the role of the insider who bought CervoMed (CRVO) shares?

The reporting person is an officer of CervoMed, serving as the company’s Chief Commercial and Business officer.

Were the CervoMed (CRVO) shares purchased in open-market transactions?

Yes. The explanation of responses states that the shares were purchased in open-market transactions.

Does the insider provide details about the trade price breakdown for CervoMed (CRVO) shares?

Yes. The insider notes that trades occurred between $7.53 and $7.60 and undertakes to provide full detail on the number of shares bought at each price within that range upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 09:01 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winton Matthew

(Last) (First) (Middle)

C/O CERVOMED INC.

20 PARK PLAZA, SUITE 424

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CervoMed Inc. [ CRVO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial and Business

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		P		10,000(1)	A	$7.57(2)	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares purchased in open-market transactions.

2. The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.53 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range.

	/s/ William R. Elder, attorney-in-fact for the Reporting Person	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.